Editorial Note: This resource was originally published on February 24, 2025, and has been updated throughout 2025 and 2026 to reflect the rapid and evolving landscape of federal executive actions concerning LGBTQ+ health and care access.
Since the first day of his second term, President Donald Trump has fundamentally reshaped the role of the federal government in the lives of LGBTQ+ individuals, particularly regarding healthcare access, data collection, and the definition of gender identity in federal law. This report tracks the systemic dismantling of the Biden-era protections and the implementation of a new administrative framework that prioritizes a binary, biological definition of sex across all federal agencies.
Main Facts: A New Federal Paradigm
The cornerstone of this shift is the executive branch’s move to define sex as an "immutable biological classification" linked to reproductive anatomy, explicitly rejecting the concept of gender identity. This redefinition is not merely rhetorical; it serves as the legal foundation for a suite of executive orders, agency memoranda, and rulemaking processes that have systematically rescinded nondiscrimination protections, restricted federal funding for gender-affirming care (GAC), and initiated high-level investigations into medical providers and professional organizations.
The administration has characterized its actions as a return to "biological truth" and a defense of children against what it terms "gender ideology." Conversely, public health experts, civil rights organizations, and major medical associations argue that these policies represent an unprecedented intervention into clinical practice, undermining evidence-based medicine and jeopardizing the health outcomes of the LGBTQ+ community.
Chronology of Key Executive Actions
The administration’s policy agenda was launched immediately upon inauguration. Below are the pivotal moments in this ongoing shift:
- January 20, 2025: President Trump issues initial rescissions of Biden-era executive orders, including EO 13988 (Preventing and Combating Discrimination on the Basis of Gender Identity or Sexual Orientation) and EO 14075 (Advancing Equality for LGBTQI+ Individuals).
- January 28, 2025: Issuance of the executive order "Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government," which mandates that all federal agencies remove references to gender identity and cease funding for programs deemed to promote "gender ideology."
- January 28, 2025: Simultaneous issuance of the order "Protecting Children From Chemical and Surgical Mutilation," targeting youth access to gender-affirming care through Medicaid, Medicare, and federal research grants.
- February 20, 2025: HHS formally rescinds the "Notice and Guidance on Gender Affirming Care, Civil Rights, and Patient Privacy," which had previously affirmed that Section 1557 of the Affordable Care Act protected against discrimination based on gender identity.
- May 2025–June 2026: A series of investigative actions, including grand jury subpoenas issued to major health systems like NYU Langone, Stanford Children’s, and Mount Sinai, signals an escalation from administrative oversight to potential criminal investigations into the provision of gender-affirming care.
The Regulatory and Investigative Landscape
The administration has utilized three primary mechanisms to enforce its new policy: the withholding of federal funds, the aggressive use of the Federal Food, Drug, and Cosmetic Act, and the commissioning of reports that challenge established medical consensus.
The Role of the DOJ and FTC
In a significant departure from previous norms, the Department of Justice (DOJ) has moved to characterize the provision of gender-affirming medical care for minors as potential "healthcare fraud." By leveraging the False Claims Act and the Food, Drug, and Cosmetic Act, the DOJ has created a high-stakes environment for hospitals. The resolution with Texas Children’s Hospital—in which the institution agreed to pay $10 million and establish a "detransition clinic"—serves as a template for the administration’s strategy of tying medical practice to massive financial and legal penalties.
Simultaneously, the Federal Trade Commission (FTC) has engaged in a campaign against professional bodies. By issuing Civil Investigative Demands (CIDs) to the American Academy of Pediatrics, the Endocrine Society, and the World Professional Association for Transgender Health (WPATH), the FTC has sought to frame the dissemination of evidence-based clinical guidelines as "deceptive marketing practices."
Data Collection and Research
The administration has effectively halted the collection of Sexual Orientation and Gender Identity (SOGI) data within the Medicaid program and other federal health surveys. By removing these questions, the administration has made it statistically difficult to track health disparities or the efficacy of public health interventions for LGBTQ+ populations. Furthermore, the CDC’s updated "About" page now explicitly lists the deprioritization of DEI initiatives as a core agency mission, signaling a permanent change in how public health resources are allocated.
Implications for Public Health and Care Access
The implications of these actions are broad, affecting everything from HIV care to mental health support for transgender youth.
The "Chilling Effect" on Providers
The most immediate consequence of the administration’s actions is the "chilling effect" felt by healthcare providers nationwide. When the federal government threatens to strip hospitals of Medicare/Medicaid funding or launches grand jury investigations into the billing of hormones and puberty blockers, the risk-to-reward ratio for providing such care becomes unsustainable for many institutions.
Even in states where gender-affirming care remains legal, many hospitals have preemptively curtailed their services to avoid becoming the target of an administrative subpoena or an HHS Office of Inspector General (OIG) investigation. This has led to the closure of specialized clinics, leaving thousands of patients—many of whom are low-income and reliant on public programs—without access to necessary medical supervision.
Impact on HIV and Marginalized Populations
The Ryan White HIV/AIDS Program, which provides critical care to vulnerable populations, has seen its scope narrowed. New guidance explicitly prohibits the use of program funds for any gender-affirming interventions. Because many patients with HIV also seek gender-affirming care, the integration of these services was previously seen as a "whole person" approach. By forcing a separation between HIV care and gender-affirming care, the administration has introduced a new hurdle to care engagement, which public health experts warn could lead to higher rates of viral load non-suppression and poorer long-term health outcomes for transgender people living with HIV.
Misinformation and the Erosion of Medical Consensus
The administration has relied heavily on reports—such as the HHS review "Wolves in White Coats"—that contrast sharply with the positions held by the American Medical Association, the American Psychological Association, and other leading health authorities. By labeling evidence-based medical treatments as "radical gender experimentation," the administration is fostering a climate of public distrust in medical institutions. This strategy, often referred to as "politicized medicine," effectively uses the apparatus of the state to reject clinical evidence in favor of an ideological framework.
Judicial Challenges and Legal Standing
The legality of these actions has been the subject of intense litigation. The court system has become a central battleground, with mixed results for the administration.
- Temporary Restraining Orders (TROs): Throughout 2025 and 2026, various federal courts issued TROs to block the enforcement of provisions that would withhold federal funding from hospitals providing gender-affirming care.
- The Tennessee v. Kennedy Ruling: In a significant blow to the administration, a federal judge in early 2026 vacated the HHS declaration that sought to unilaterally establish "standards of care" that would have banned gender-affirming care for minors. The court found that HHS lacked the statutory authority to bypass established professional standards.
- Class Action Protections: In response to the grand jury subpoenas, patient families have successfully formed provisional classes in jurisdictions like New York and California, securing injunctions that prevent hospitals from releasing sensitive, patient-identifying health information to the DOJ.
Despite these judicial victories, the administration has maintained a strategy of appealing unfavorable rulings, keeping cases in "abeyance," and using the threat of litigation to maintain its policy objectives.
Conclusion: A Fundamental Reordering
The second Trump administration has succeeded in creating a federal policy environment that is fundamentally hostile to the recognition and medical support of transgender identity. By linking funding to ideology, utilizing the investigative power of the DOJ and FTC to intimidate providers, and systematically removing LGBTQ+ individuals from the scope of federal nondiscrimination protections, the administration has achieved a far-reaching reordering of health policy.
As of mid-2026, the long-term impact of these policies remains in flux. While the court system continues to act as a check on the most extreme administrative overreaches, the cumulative impact of these actions—the shuttering of clinics, the loss of data, and the erosion of professional standards—will likely be felt for a generation. The tension between the federal government’s mandate to "restore biological truth" and the medical community’s commitment to evidence-based, patient-centered care remains one of the most significant domestic policy conflicts of the decade.
About the Author
